ESMO advanced ovarian cancer

February 22 ESMO advanced ovarian cancer Valencia, Spain

EuroTides

November 6 EuroTides Amsterdam, The Netherlands

Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

Maastricht, The Netherlands, 2nd November 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO). […]

Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

Maastricht, The Netherlands, 25th October 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer. CPC634 is a new drug […]

ESMO 36th Annual Congress 2018

October 19-23 ESMO 36th Annual Congress 2018 Munich, Germany

BioJapan

October 10-12 BioJapan Yokohama, Japan

Clinam 11

September 2-5 Clinam 11 Basel, Switzerland

Gordon Research Conference

August 12-18 Gordon Research Conference Mount Snow, USA

The Koch institute – MIT nanomedicines

June 15 The Koch institute – MIT nanomedicines Boston/Cambridge, USA

Bio International Convention

June 4-7 Bio International Convention Boston, USA